Gilead Sciences's most recent trend suggests a bullish bias. One trading opportunity on Gilead Sciences is a Bull Put Spread using a strike $66.00 short put and a strike $61.00 long put offers a potential 21.95% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $66.00 by expiration. The full premium credit of $0.90 would be kept by the premium seller. The risk of $4.10 would be incurred if the stock dropped below the $61.00 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Gilead Sciences is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Gilead Sciences is bullish.
The RSI indicator is at 72.76 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
Diodes Incorporated to Announce Fourth Quarter and Fiscal 2020 Financial Results on February 16
Mon, 25 Jan 2021 22:00:00 +0000
Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Tuesday, February 16, 2021 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its fourth quarter and fiscal 2020 financial results.
3 Blockbuster Drug Launches to Watch This Year
Sun, 24 Jan 2021 13:53:00 +0000
The coronavirus pandemic has impacted lots of industries but it didn't slow down the pace of new drug approvals. The FDA greenlighted 59 new drugs last year, and 2021 is shaping up to be a big year too. Read on to see why new drugs from GlaxoSmithKline (NYSE: GSK), Gilead Sciences (NASDAQ: GILD), and Eli Lilly (NYSE: LLY) made the list.
Better Buy: Gilead Sciences vs. Pfizer
Sat, 23 Jan 2021 11:08:00 +0000
One has a top COVID-19 treatment, the other has a top COVID-19 vaccine. Which stock will come out on top.
Where Will Sorrento Therapeutics Be in 1 Year?
Fri, 22 Jan 2021 11:48:00 +0000
Last year, Sorrento Therapeutics (NASDAQ: SRNE) became one of the hottest coronavirus stocks. The enormous volatility behind Sorrento stock is not without reason. After the development of its coronavirus tests and therapeutics began to stall, shareholders started ditching the company in favor of its competitors.
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021
Thu, 21 Jan 2021 21:01:00 +0000
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 4, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s fourth quarter and full year 2020 financial results and will provide a business update.
Also on Market Tamer…
Follow Us on Facebook